查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930035

脑肿瘤药物市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2025-2034）

Brain Tumor Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 181 Pages | 商品交期: 请询问到货日

价格

脑肿瘤药物市场成长因素

全球脑肿瘤药物市场正经历稳定成长，主要受脑肿瘤发生率上升、诊断技术进步、药物研发投入增加的推动。 2025年，全球市场规模为22.9亿美元。预计到2026年将成长至25.5亿美元，到2034年将达到52亿美元，在预测期（2026-2034年）内复合年增长率（CAGR）为9.30%。

北美市场占主导地位，2025年市占率达43.38%。这得益于其强有力的医疗保险政策、先进的医疗基础设施以及强大的抗癌药物研发管线。美国脑瘤药物市场预计将显着成长，到 2030 年将达到 14.7 亿美元。

脑瘤是由于脑内细胞不受控制地生长而形成的异常组织肿块。它们分为原发性脑瘤和转移性脑瘤。原发性脑瘤起源于脑部，而转移性脑瘤则从其他器官扩散而来。原发性脑瘤占全球确诊病例的大多数。

市场驱动因素

脑瘤发生率上升

全球脑瘤发生率的上升是市场成长的主要驱动因素。生活方式的改变、吸烟、老化、辐射暴露和环境因素都导致了癌症发生率的上升。脑瘤约占所有癌症病例的 1-2%，但死亡率很高。

根据国际癌症研究机构 (IARC) 的数据，全球脑肿瘤发生率预计将从 2024 年的 308,102 例增加到 2040 年的 415,183 例。由于诊断和治疗率的提高，尤其是在北美和亚太地区，对脑肿瘤药物的需求正在增长。

强大的在研药物和研发投入

强大的在研药物管线进一步支撑了市场。预计到 2025 年，将有超过 150 种脑肿瘤候选药物进入临床开发阶段。各国政府和研究机构正积极资助脑肿瘤研究，以满足尚未满足的医疗需求。例如，2022 年 10 月，澳洲政府承诺拨款 400 万美元支持脑肿瘤研究计画。

市场趋势

诊断技术与个人化医疗的进步

由于血脑障壁对药物输送的限制，脑肿瘤的早期诊断仍面临挑战。然而，分子诊断、液体活检和基因生物标记分析的进步正在改善早期检测和治疗效果。

循环肿瘤DNA分析和基于血液的诊断测试等创新技术正日益受到关注。 2023年1月，Datar Cancer Genetics公司用于检测恶性脑肿瘤的TriNetr-Glio液体活检测试获得了美国FDA的突破性疗法认定。这些进步有望提高诊断率和药物应用率。

新冠疫情的影响

新冠疫情期间，由于诊断和治疗的延误，脑肿瘤药物市场受到了不利影响。根据美国疾病管制与预防中心 (CDC) 的数据，2024 年癌症发生率较 2019 年下降 11%，主要原因是筛检率下降。主要公司也面临供应链中断和收入下降的问题。例如，罗氏公司报告称，2024 年其阿瓦斯汀 (Avastin) 的收入下降了 29.4%。然而，随着疫情后医疗服务的恢復，市场开始復苏。

市场区隔分析

依疗法划分

此市场细分包括化疗、标靶治疗、免疫疗法和其他疗法。

化疗仍是脑肿瘤一线和辅助治疗的主流，预计到2026年将占38.49%的市场占有率。

由于核准药物的增加、临床合作的进展以及精准医疗的进步，预计将标靶治疗和免疫治疗领域快速成长。

依适应症划分

适应症包括胶质瘤、脑膜瘤、脑下垂体瘤等。

预计到2026年，胶质瘤领域将以41.24%的市占率领先，这主要得益于恶性胶质瘤的高发生率以及越来越多的胶质母细胞瘤治疗药物的推出。

依通路划分

预计到2026年，医院药局管道将以94.25%的市占率占主导地位。这是因为这些药物需要医院管理和保险报销。由于门诊治疗的增加，零售药局和网路药局正在逐步扩张。

区域洞察

  • 北美：预计到 2025 年将达到 10 亿美元，2026 年将达到 11 亿美元，这主要得益于 FDA 的批准和完善的报销体系。
  • 欧洲：预计到 2025 年将占 26.83% 的市场占有率，这主要得益于孤儿药认定和监管支持。
  • 亚太地区：预计到 2025 年将占 18.98% 的市场占有率，由于公众意识的提高和诊断技术的进步，其复合年增长率最高。
  • 拉丁美洲以及中东和非洲地区由于其完善的医疗保健基础设施，正在稳步扩张。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 2024/2025年主要地区脑肿瘤发生率
  • 主要产业趋势－併购、合作与收购
  • 主要地区和国家监管概览
  • 主要公司新产品发布
  • 新冠疫情对脑肿瘤药物市场的影响

第五章 全球脑瘤市场

肿瘤药物市场分析、洞察与预测（2025-2034）
  • 市场分析、洞察与预测 - 按疗法分类
    • 标靶治疗
    • 化疗
    • 免疫疗法
    • 其他
  • 市场分析、洞察与预测 - 按适应症分类
    • 脑下垂体瘤
    • 脑膜瘤
    • 胶质母细胞瘤
    • 其他
  • 市场分析、洞察与预测 - 依销售管道分类
    • 医院药房
    • 零售及线上药房
  • 市场分析、洞察与预测 - 按地区分类
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东及非洲

第六章 北美脑瘤药物市场分析、洞察与预测（2025-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲脑肿瘤药物市场分析、洞察与预测（2025-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区脑肿瘤药物市场分析、洞察与预测（2025-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

    第九章：拉丁美洲脑瘤药物市场分析、洞察与预测（2025-2034）

    • 依国家划分
      • 巴西
      • 墨西哥
      • 拉丁美洲其他地区

      第十章：中东与非洲脑瘤药物市场分析、洞察与预测（2025-2034）

      • 依国家划分
        • 海湾合作委员会
        • 南非
        • 中东其他地区东非和非洲

      第十一章 竞争分析

      • 全球市占率分析（2025 年）
      • 公司简介
      • 辉瑞公司
      • 罗氏公司
      • 诺华公司
      • 默克公司
      • 安尼尔製药股份有限公司
      • 安进公司
      • NextSource药厂股份有限公司
      • Emcure製药公司
Product Code: FBI105025

Growth Factors of brain tumor drugs Market

The global brain tumor drugs market is witnessing steady growth driven by the rising incidence of brain cancer, advancements in diagnosis, and increasing investment in drug development. In 2025, the global market was valued at USD 2.29 billion. It is projected to grow to USD 2.55 billion in 2026 and further reach USD 5.2 billion by 2034, registering a CAGR of 9.30% during the forecast period (2026-2034).

North America dominated the market with a 43.38% share in 2025, supported by strong reimbursement policies, advanced healthcare infrastructure, and a robust pipeline of oncology drugs. The U.S. brain tumor drugs market is expected to grow significantly, reaching USD 1.47 billion by 2030.

Brain tumors are abnormal masses of tissue caused by uncontrolled cell growth in the brain. They are classified into primary tumors, originating in the brain, and metastatic tumors, which spread from other organs. Primary tumors account for the majority of diagnosed cases globally.

Market Drivers

Rising Prevalence of Brain Cancer

The increasing prevalence of brain tumors worldwide is a major factor driving market growth. Lifestyle changes, smoking, aging populations, exposure to radiation, and environmental factors have contributed to rising cancer incidence. Brain tumors account for nearly 1-2% of total cancer cases, yet they exhibit a high mortality rate.

According to the International Agency for Research on Cancer, global brain cancer incidence is expected to rise from 308,102 cases in 2024 to 415,183 cases by 2040. Increasing diagnosis and treatment rates, particularly in North America and Asia Pacific, are boosting the demand for brain tumor drugs.

Strong Pipeline and R&D Investments

The market is further supported by a strong pipeline of investigational drugs. By 2025, more than 150 brain tumor drug candidates were under clinical development. Governments and research organizations are actively funding brain cancer research to address unmet medical needs. For instance, in October 2022, the Australian government allocated USD 4.0 million to support brain cancer research initiatives.

Market Trends

Advancements in Diagnosis and Personalized Medicine

Early diagnosis of brain tumors remains challenging due to the blood-brain barrier, which limits drug delivery. However, advancements in molecular diagnostics, liquid biopsy, and genetic biomarker analysis are improving early detection and treatment outcomes.

Innovations such as circulating tumor DNA analysis and blood-based diagnostic tests are gaining traction. In January 2023, Datar Cancer Genetics received U.S. FDA breakthrough designation for TriNetr-Glio, a liquid biopsy test for detecting malignant brain tumors. These advancements are expected to increase diagnosis rates and drug adoption.

COVID-19 Impact

The brain tumor drugs market was negatively impacted during the COVID-19 pandemic due to delayed diagnosis and treatment. According to the CDC, cancer incidence declined by 11% in 2024 compared to 2019, primarily due to reduced screenings. Major players also faced supply chain disruptions and revenue declines. For instance, F. Hoffmann-La Roche Ltd. reported a 29.4% decline in Avastin revenues in 2024. However, market recovery began as healthcare services resumed post-pandemic.

Market Segmentation Analysis

By Therapy

The market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.

The chemotherapy segment dominated the market with a 38.49% share in 2026, as it remains the first-line and adjuvant treatment for brain tumors.

Targeted therapy and immunotherapy segments are expected to grow rapidly due to increasing approvals, clinical collaborations, and advancements in precision medicine.

By Indication

Based on indication, the market includes glioma, meningioma, pituitary, and others.

The glioma segment led the market with a 41.24% share in 2026, driven by the high prevalence of malignant gliomas and increasing drug launches for glioblastoma treatment.

By Distribution Channel

The hospital pharmacy segment dominated the market with a 94.25% share in 2026, as these drugs require hospital-based administration and insurance reimbursement. Retail and online pharmacies are gradually expanding with increased outpatient treatment.

Regional Insights

  • North America: Valued at USD 1.0 billion in 2025 and USD 1.1 billion in 2026, driven by FDA approvals and strong reimbursement.
  • Europe: Held 26.83% market share in 2025, supported by orphan drug designations and regulatory support.
  • Asia Pacific: Accounted for 18.98% share in 2025 and is expected to grow at the fastest CAGR due to rising awareness and improving diagnosis.
  • Latin America and Middle East & Africa are expanding steadily due to improving healthcare infrastructure.

Competitive Landscape

The market is consolidated, with leading players such as F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Merck & Co., Amgen Inc., and Amneal Pharmaceuticals LLC. Strategic initiatives including acquisitions, FDA approvals, and pipeline expansion are strengthening market competition.

Conclusion

In conclusion, the global brain tumor drugs market is poised for consistent growth, expanding from USD 2.29 billion in 2025 to USD 5.2 billion by 2034. Rising brain cancer prevalence, strong drug pipelines, advancements in diagnostics, and increasing government support are driving market expansion. Despite challenges such as high treatment costs and limited reimbursement in developing regions, continuous innovation and regulatory approvals are expected to sustain long-term market growth.

Segmentation By Therapy

  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By Indication

  • Pituitary
  • Meningioma
  • Glioma
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Region

  • North America (By Therapy, By Indication, By Distribution Channel, and By Country)
    • U.S. (By Indication)
    • Canada (By Indication)
  • Europe (By Therapy, By Indication, By Distribution Channel, and By Country)
    • U.K. (By Indication)
    • Germany (By Indication)
    • France (By Indication)
    • Italy (By Indication)
    • Spain (By Indication)
    • Rest of Europe (By Indication)
  • Asia Pacific (By Therapy, By Indication, By Distribution Channel, and By Country)
    • China (By Indication)
    • Japan (By Indication)
    • India (By Indication)
    • Australia (By Indication)
    • Southeast Asia (By Indication)
    • Rest of Asia Pacific (By Indication)
  • Latin America (By Therapy, By Indication, By Distribution Channel, and By Country)
    • Brazil (By Indication)
    • Mexico (By Indication)
    • Rest of Latin America (By Indication)
  • Middle East & Africa (By Therapy, By Indication, By Distribution Channel, and By Country)
    • GCC (By Indication)
    • South Africa (By Indication)
    • Rest of Middle East & Africa (By Indication)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence of Brain Cancer, Key Region, 2024/2025
  • 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
  • 4.3. Overview of the Regulatory Scenario by Key Region/Countries
  • 4.4. New Product Launches by Key Players
  • 4.5. Impact of COVID-19 on Brain Tumor Drugs Market

5. Global Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy
    • 5.1.1. Targeted Therapy
    • 5.1.2. Chemotherapy
    • 5.1.3. Immunotherapy
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Pituitary Tumors
    • 5.2.2. Meningioma
    • 5.2.3. Glioblastoma
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail & Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy
    • 6.1.1. Targeted Therapy
    • 6.1.2. Chemotherapy
    • 6.1.3. Immunotherapy
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Pituitary Tumors
    • 6.2.2. Meningioma
    • 6.2.3. Glioblastoma
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail & Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Indication
    • 6.4.2. Canada
      • 6.4.2.1. By Indication

7. Europe Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy
    • 7.1.1. Targeted Therapy
    • 7.1.2. Chemotherapy
    • 7.1.3. Immunotherapy
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Pituitary Tumors
    • 7.2.2. Meningioma
    • 7.2.3. Glioblastoma
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail & Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. Germany
      • 7.4.1.1. By Indication
    • 7.4.2. U.K.
      • 7.4.2.1. By Indication
    • 7.4.3. France
      • 7.4.3.1. By Indication
    • 7.4.4. Spain
      • 7.4.4.1. By Indication
    • 7.4.5. Italy
      • 7.4.5.1. By Indication
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Indication
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Indication

8. Asia Pacific Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy
    • 8.1.1. Targeted Therapy
    • 8.1.2. Chemotherapy
    • 8.1.3. Immunotherapy
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Pituitary Tumors
    • 8.2.2. Meningioma
    • 8.2.3. Glioblastoma
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail & Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Indication
    • 8.4.2. China
      • 8.4.2.1. By Indication
    • 8.4.3. India
      • 8.4.3.1. By Indication
    • 8.4.4. Australia
      • 8.4.4.1. By Indication
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Indication
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Indication

9. Latin America Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy
    • 9.1.1. Targeted Therapy
    • 9.1.2. Chemotherapy
    • 9.1.3. Immunotherapy
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Pituitary Tumors
    • 9.2.2. Meningioma
    • 9.2.3. Glioblastoma
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail & Online Pharmacy
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Indication
    • 9.4.2. Mexico
      • 9.4.2.1. By Indication
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Indication

10. Middle East & Africa Brain Tumor Drugs Market Analysis, Insights and Forecast, 2025-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy
    • 10.1.1. Targeted Therapy
    • 10.1.2. Chemotherapy
    • 10.1.3. Immunotherapy
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Indication
    • 10.2.1. Pituitary Tumors
    • 10.2.2. Meningioma
    • 10.2.3. Glioblastoma
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail & Online Pharmacy
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Indication
    • 10.4.2. South Africa
      • 10.4.2.1. By Indication
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Indication

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview,
      • 11.2.1.2. Product,
      • 11.2.1.3. SWOT Analysis,
      • 11.2.1.4. Recent Developments,
      • 11.2.1.5. Strategies,
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. F. Hoffmann-La Roche Ltd
      • 11.2.2.1. Overview,
      • 11.2.2.2. Product,
      • 11.2.2.3. SWOT Analysis,
      • 11.2.2.4. Recent Developments,
      • 11.2.2.5. Strategies,
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Novartis AG
      • 11.2.3.1. Overview,
      • 11.2.3.2. Product,
      • 11.2.3.3. SWOT Analysis,
      • 11.2.3.4. Recent Developments,
      • 11.2.3.5. Strategies,
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Merck & Co. Inc.
      • 11.2.4.1. Overview,
      • 11.2.4.2. Product,
      • 11.2.4.3. SWOT Analysis,
      • 11.2.4.4. Recent Developments,
      • 11.2.4.5. Strategies,
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Amneal Pharmaceuticals LLC.
      • 11.2.5.1. Overview,
      • 11.2.5.2. Product,
      • 11.2.5.3. SWOT Analysis,
      • 11.2.5.4. Recent Developments,
      • 11.2.5.5. Strategies,
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Amgen Inc.
      • 11.2.6.1. Overview,
      • 11.2.6.2. Product,
      • 11.2.6.3. SWOT Analysis,
      • 11.2.6.4. Recent Developments,
      • 11.2.6.5. Strategies,
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. NextSource Pharmaceuticals, LLC
      • 11.2.7.1. Overview,
      • 11.2.7.2. Product,
      • 11.2.7.3. SWOT Analysis,
      • 11.2.7.4. Recent Developments,
      • 11.2.7.5. Strategies,
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Emcure Pharmaceuticals
      • 11.2.8.1. Overview,
      • 11.2.8.2. Product,
      • 11.2.8.3. SWOT Analysis,
      • 11.2.8.4. Recent Developments,
      • 11.2.8.5. Strategies,
      • 11.2.8.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 2: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 3: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 4: Global Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Region, 2025-2034
  • Table 5: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 6: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 7: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 8: North America Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country, 2025-2034
  • Table 9: U.S. Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 10: Canada Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 11: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 12: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 13: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 14: Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 15: Germany Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 16: U.K. Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 17: France Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 18: Italy Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 19: Spain Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 20: Scandinavia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 21: Rest of Europe Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 22: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 23: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 24: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 25: Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 26: Japan Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 27: India Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 28: China Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 29: Australia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 30: Southeast Asia Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 31: Rest of Asia Pacific Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 32: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 33: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 34: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 35: Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 36: Brazil Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 37: Mexico Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 38: Rest of Latin America Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 39: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Therapy, 2025-2034
  • Table 40: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 41: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 42: Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 43: GCC Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 44: South Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034
  • Table 45: Rest of Middle East & Africa Brain Tumor Drugs Market Revenue (USD billion) Forecast, by Indication, 2025-2034

List of Figures

  • Figure 1: Global Brain Tumor Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Brain Tumor Drugs Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 3: Global Brain Tumor Drugs Market Forecast (USD billion), by Targeted Therapy, 2025-2034
  • Figure 4: Global Brain Tumor Drugs Market Forecast (USD billion), by Chemotherapy, 2025-2034
  • Figure 5: Global Brain Tumor Drugs Market Forecast (USD billion), by Immunotherapy, 2025-2034
  • Figure 6: Global Brain Tumor Drugs Market Forecast (USD billion), by Others, 2025-2034
  • Figure 7: Global Brain Tumor Drugs Market Value Share (%), by Indication, 2025 & 2034
  • Figure 8: Global Brain Tumor Drugs Market Forecast (USD billion), by Pituitary Tumors, 2025-2034
  • Figure 9: Global Brain Tumor Drugs Market Forecast (USD billion), by Meningioma, 2025-2034
  • Figure 10: Global Brain Tumor Drugs Market Forecast (USD billion), by Glioblastoma, 2025-2034
  • Figure 11: Global Brain Tumor Drugs Market Forecast (USD billion), by Others, 2025-2034
  • Figure 12: Global Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 13: Global Brain Tumor Drugs Market Forecast (USD billion), by Hospital Pharmacy, 2025-2034
  • Figure 14: Global Brain Tumor Drugs Market Forecast (USD billion), by Retail & Online Pharmacy, 2025-2034
  • Figure 15: Global Brain Tumor Drugs Market Value (USD billion), by Region, 2025 & 2034
  • Figure 16: North America Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 17: North America Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 18: North America Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 19: North America Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 20: North America Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 21: North America Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 22: North America Brain Tumor Drugs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 23: North America Brain Tumor Drugs Market Value Share (%), By Country, 2025
  • Figure 24: Europe Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 25: Europe Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 26: Europe Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 27: Europe Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 28: Europe Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 33: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 34: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 35: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 36: Asia Pacific Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 37: Asia Pacific Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 38: Asia Pacific Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 39: Asia Pacific Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 40: Latin America Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 41: Latin America Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 42: Latin America Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 43: Latin America Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 44: Latin America Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 45: Latin America Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 46: Latin America Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 47: Latin America Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 48: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 49: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Therapy, 2025
  • Figure 50: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 51: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Indication, 2025
  • Figure 52: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Middle East & Africa Brain Tumor Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Middle East & Africa Brain Tumor Drugs Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Middle East & Africa Brain Tumor Drugs Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Global Brain Tumor Drugs Market Share (%), By Company, 2025